side-effectsMay 11, 2026·5 min read

CJC-1295 + Ipamorelin Side Effects: Trial Data

Injection-site reactions and brief flushing dominate. Hand tingling and water retention cluster in community data. Full safety breakdown.

Save

CJC-1295 + ipamorelin side effects from trial and community data

The CJC-1295 + ipamorelin combo is the most-discussed GHRH + GHRP stack in the research-peptide community. Each component has published research; the combined formulation has not been formally trialed. CJC-1295's Phase 1 and Phase 2 data (Teichman et al., PMID 16352683; Jetté et al., PMID 15817669) and ipamorelin's preclinical and Phase 1 work (Raun et al., PMID 9849822; Ankersen et al., PMID 9733495) anchor the adverse-event picture. Community self-reports of the combination fill in the practical day-to-day events.

Research-context information only. CJC-1295 and ipamorelin are research peptides. Protocols, doses, and reactions reported below come from published research on each peptide separately and self-reported community sources for the combined stack. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

This article separates published trial-grade data for each component from self-reported community data on the combined stack.

Component-Level Trial Findings

CJC-1295 (without DAC, modified GRF 1-29)

Phase 1 and Phase 2 work described:

  • Dose-dependent GH elevation (2-10x baseline at studied doses, PMID 16352683)
  • IGF-1 elevation of 1.5-3x baseline at 1-2 weeks
  • Mild facial flushing post-injection in some participants
  • No serious adverse events at studied doses

CJC-1295 with DAC

The DAC-modified version covalently binds to albumin, extending half-life to 5-8 days (PMID 16352683). Sustained elevated GH and IGF-1 are the pharmacologic feature. Published data describe:

  • Sustained IGF-1 elevation at 5-8 days post-injection
  • Greater water retention and hand-tingling reports than non-DAC in community sources
  • Trial data on serious adverse events: none reported at studied doses

Ipamorelin

The Raun and Ankersen papers (PMID 9849822; PMID 9733495) established ipamorelin as a selective GH secretagogue without significant elevation of ACTH, cortisol, or prolactin — distinguishing it from older GHRPs. Published findings include:

  • Clean endocrine profile (no significant ACTH/cortisol/prolactin spike)
  • GH peak at approximately 40 minutes post-injection
  • Return to baseline within 3 hours
  • No significant hunger stimulation (unlike GHRP-6)

CJC-1295 + ipamorelin combined event chart

Top CJC-1295 + Ipamorelin Vendors

Ranked by price, COA availability, and reputation

1
Nura PeptidePREMIUMCOA
10/10
10mg$5.50/mg
2
Ascension PeptidesCOA
9.9/10
20mg$3.20/mg
3
Ion PeptideCOA
9.8/10
10mg$5.90/mg
See full vendor rankings for CJC-1295 + Ipamorelin →

Self-Reported Community Adverse Events for the Combination

Note on labeling: the events below come from r/peptides, r/PeptideTherapy, and peptide forums for the combined CJC-1295 + ipamorelin stack. They are not from trials of the combined product (which do not exist).

Injection-site reactions

The most consistent community feedback. Mild redness, itching, or a small warm welt at the subcutaneous injection site, typically lasting under 24 hours. Site rotation and warming the vial to room temperature are the two factors community sources most consistently describe as reducing reaction frequency.

Facial flushing within 10-20 minutes post-injection

Community sources commonly describe a brief warmth and visible flush in the face, fading within 30 minutes. This is attributed to CJC-1295 rather than ipamorelin, consistent with published findings on CJC-1295 alone.

Hand tingling or "fluid feel"

The most consistent community feedback for the first 2-4 weeks at higher doses. Self-reported community sources describe tingling or numbness in the hands, sometimes attributed to GH-induced fluid retention causing median-nerve compression (a classic GH-elevation effect documented in tesamorelin labeling).

First-week fatigue or vivid dreams

Community reports cluster around vivid dreams or restless sleep in the first week of evening administration, sometimes attributed by community sources to deeper REM episodes from GH pulse alignment with sleep cycle.

Hunger changes

Less consistently reported. Ipamorelin's published mechanism does not stimulate appetite (PMID 9849822), so meaningful hunger changes in community reports of the combination are uncommon. When they appear, community sources commonly attribute them to vendor product variation rather than the peptides themselves.

Less Commonly Reported Events

  • Brief headache during the first 1-3 doses — community sources describe dose-splitting to resolve.
  • Sleep-pattern shifts — more commonly reported with CJC-1295 with DAC than non-DAC.
  • Glucose-related lightheadedness — sparse reports, attributed by community sources to GH-induced shifts in insulin sensitivity.

IGF-1 Monitoring Patterns

Community sources commonly describe IGF-1 measurement at baseline, 6-8 weeks, and 16-24 weeks. Self-reported community sources describe dose reduction when IGF-1 exceeds the lab's upper reference limit. Published CJC-1295 data (PMID 16352683) showed IGF-1 elevations of 1.5-3x baseline at studied doses; the upper end of that range can exceed typical lab reference ranges.

The community pattern aligns with FDA labeling practice for the related tesamorelin product, which recommends IGF-1 monitoring and dose-modification at protocol-defined thresholds.

Dose-Response Patterns

CJC-1295's Phase 1 data established dose-proportional GH and IGF-1 elevation across the studied dose range. Ipamorelin's preclinical work showed dose-proportional GH peak amplitude up to a saturating dose, after which higher doses did not produce higher GH responses.

Self-reported community sources describe the combined stack's adverse-event picture as scaling with daily dose: site reactions, flushing, and hand-tingling all reportedly more common at the higher end of community-reported doses (above 300 mcg of each per day).

30ml bacteriostatic water vial — 0.9% benzyl alcohol multi-dose
Bac Water Made for Peptides
Don't risk a $300 peptide on generic bac water.
Most cloudy reconstitutions trace back to one thing — and it isn't the peptide. Sterile, non-pyrogenic, 0.9% benzyl alcohol — formulated for peptide reconstitution, not repackaged from generic stock.
✓ 0.9% benzyl alcohol✓ Made for peptides✓ 30 mL multi-dose
See why our bac water doesn't ruin peptides
30ml from $18.75 · Ships fast · Code thepeptidecatalog

Dose-Pause and Discontinuation Patterns

The published trials of each component allowed dose-interruption for protocol-defined adverse events. Discontinuation rates were low across CJC-1295's Phase 1 and 2 work and across ipamorelin's Phase 1 development.

Community sources describe two patterns. Pause-and-resume — short 3-5 day breaks when hand-tingling or sleep disruption becomes intrusive. Dose-cycling — community sources commonly describe 8-week-on / 4-week-off cycles, citing IGF-1 normalization during off-cycles as the rationale.

CJC-1295 + ipamorelin endocrine pathway diagram

Core Supplies for This Protocol

The essentials for running any reconstituted injectable: cold storage, accurate syringes, alcohol prep pads, and metabolic tracking.

Cooluli Classic 4L Mini Fridge
Storage

Cooluli Classic 4L Mini Fridge

Compact thermoelectric mini-fridge with heat/cool toggle. The most-mentioned dedicated peptide-storage fridge in research community sources — fits ~20 vials and runs quietly.

View on Amazon →
BD Ultra-Fine 31G 0.3cc 5/16" Insulin Syringes (Box of 90)
Injection

BD Ultra-Fine 31G 0.3cc 5/16" Insulin Syringes (Box of 90)

0.3cc 31G syringes — each gradation marks 1 unit (vs 2 units on 1cc), making sub-50-unit peptide doses accurate. BD Ultra-Fine is the most widely-cited brand in peptide community sources.

View on Amazon →
Med-Pride Alcohol Prep Pads — Medical-Grade, Individually Wrapped
Injection

Med-Pride Alcohol Prep Pads — Medical-Grade, Individually Wrapped

Medical-grade 70% isopropyl alcohol prep pads, individually wrapped and sterile single-use. Standard for cleaning vial stoppers and injection sites before sub-Q dosing.

View on Amazon →
CONTOUR NEXT GEN Glucose Meter All-In-One Kit
Tracking

CONTOUR NEXT GEN Glucose Meter All-In-One Kit

Ascensia's CONTOUR NEXT GEN — the most clinically-validated home glucose meter. Includes 20 test strips + lancing device. Tracks the blood-sugar response GLP-1 users care about, especially during dose escalation.

View on Amazon →

As an Amazon Associate, The Peptide Catalog earns from qualifying purchases.

Full catalog →

Frequently Asked Questions

What side effects do CJC-1295 + ipamorelin trials and community sources report?
Injection-site reactions dominate both trial and community reports. CJC-1295 Phase 2 trials reported flushing and modest IGF-1 elevation (Teichman et al., PMID 16352683). Ipamorelin's clean ACTH/cortisol/prolactin profile (Raun et al., PMID 9849822) keeps the combined stack's endocrine side-effect picture narrow.
Does the combination cause more side effects than either peptide alone?
Published trials evaluated CJC-1295 and ipamorelin separately, not as a combined product. Self-reported community data describes the combined adverse-event picture as approximately the sum of the two individual peptides' patterns, with injection-site reactions being the most consistent overlap.
Why do users describe hand tingling on this stack?
Self-reported community data describes transient hand numbness or tingling in the first 2-4 weeks at higher dose ranges, attributed to GH-induced fluid retention affecting median-nerve compression. The pattern resolves with dose reduction in nearly all community reports.
Does this combination raise IGF-1 to risky levels?
CJC-1295's Phase 2 data described IGF-1 elevations of 1.5-3x baseline (Teichman et al., PMID 16352683). Community sources describe IGF-1 monitoring at 6-8 weeks, with dose reduction if values exceed the lab's upper reference limit. No trial documented adverse outcomes at the IGF-1 levels reported.
Can this combo cause sleep disruption?
Self-reported community timelines describe both directions — some users describe deeper sleep on evening administration, others describe disrupted sleep at higher doses. The mixed pattern suggests individual variation. CJC-1295 with DAC has been associated with more sleep-pattern reports than the non-DAC form.

References

Citation Topic PMID
Teichman et al., J Clin Endocrinol Metab (2006) CJC-1295 Phase 1/2 in healthy adults 16352683
Jetté et al., Endocrinology (2005) CJC-1295 GRF analog, long-lasting 15817669
Raun et al., Eur J Endocrinol (1998) Ipamorelin, first selective GH secretagogue 9849822
Ankersen et al., J Med Chem (1998) Ipamorelin GH-releasing peptide series 9733495

For educational and research purposes only. This is not medical advice. CJC-1295, ipamorelin, and their combination are not FDA-approved for any indication. Consult a healthcare provider before use.